Thudium Karen, Bilic Sanela
Novartis Pharmaceuticals, Clinical Pharmacology, Oncology Business Unit, East Hanover, NJ, USA.
Bioanalysis. 2013 Dec;5(24):2989-93. doi: 10.4155/bio.13.276.
American Association of Pharmaceutical Scientists National Biotechnology Conference Sheraton San Diego Hotel and Marina, San Diego, CA, USA, 19-23 May 2013 The National Biotechnology Conference, is a premier meeting for biotechnology professionals covering a broad range of hot topics in the biotechnology industry. Attracting participants from academia, industry and regulatory, this meeting features sessions that aim to address emerging subjects of interest and allows for open exchange between scientists. The 2013 conference featured leading researchers in the fields of antibody-drug conjugates (ADCs) and immunogenicity. Herein, we present a summary of the ADC hot topics, including bioanalytical and PK considerations, quantitative evaluation of the impact of immunogenicity and ADME to understand ADC drug-drug interactions, and clinical considerations for ADC development. This article aims to summarize the recommendations that were made by the speakers during various sessions throughout the conference.
美国药物科学家协会全国生物技术会议
2013年5月19日至23日，美国加利福尼亚州圣地亚哥市喜来登酒店及码头
全国生物技术会议是生物技术专业人士的首要会议，涵盖生物技术行业广泛的热门话题。该会议吸引了来自学术界、产业界和监管部门的参与者，设有旨在探讨新兴热门话题的会议环节，并促进科学家之间的开放交流。2013年会议的特色是抗体药物偶联物（ADC）和免疫原性领域的顶尖研究人员。在此，我们总结了ADC的热门话题，包括生物分析和药代动力学考量、免疫原性影响的定量评估以及药物代谢动力学/药物处置过程以了解ADC药物相互作用，还有ADC研发的临床考量。本文旨在总结会议期间各环节演讲者提出的建议。
